Phillip W. Kuhn Appointed Chief Commercial Officer of ISTO Technologies
Apr 8, 2014
ST. LOUIS, MO, April 8, 2014 — ISTO Technologies, Inc. (“ISTO,” the “Company”), a privately held regenerative medicine company applying its proprietary platform technologies to orthopedic and spine applications, has appointed Phillip W. Kuhn, a medical technology executive with over three decades of industry experience, as the Company’s Chief Commercial Officer. In this newly created role, Mr. Kuhn will oversee ISTO’s commercial strategy, including the execution of commercial activities relating to the sales, marketing, and product development for InQu®, the Company’s bone graft extender and substitute that is used in spinal fusion and other orthopedic applications.
“We are pleased to welcome Phil Kuhn, a strategic leader in the biologics space, to the ISTO team. Phil’s strong track record in developing new franchises and effective marketing programs while at Orthofix and Smith & Nephew has direct relevance to ISTO’s plan to build sales of InQu while developing new biologics products for orthopedic and spinal applications,” said George Dunbar, President and Chief Executive Officer of ISTO. “His hire will help raise ISTO’s profile among potential industry partners and is consistent with our goal to add relevant domain expertise that strengthens our ability to successfully execute our global strategy.”
Mr. Kuhn joins ISTO from Orthofix International N.V. a medical device company developing stimulation, spine, biologic, and orthopedic products, where as Vice President, Marketing, Orthopedics U.S. he led all U.S. and Canadian upstream and downstream product management, medical education, sales training and marketing communications.
Mr. Kuhn was previously Vice President, Strategic Marketing, at Biologics and Spine, a Smith & Nephew company, where he led that company’s orthopedic biologic development in osteoarthritis and cartilage. He previously served in commercial leadership positions at medical products companies including Abbott Laboratories, Baxter International, Cabot Medical, Ethicon Endo-Surgery and Indigo, both Johnson & Johnson companies, and Scimed, a Boston Scientific company.
A graduate of Duke University with a BA in history, Mr. Kuhn also earned an MBA in marketing from Emory University.
About ISTO Technologies, Inc.
ISTO is a privately-held regenerative medicine company developing novel products for the repair and regeneration of damaged or injured cartilage and bone. We are developing unique orthobiologic products designed to provide off-the-shelf and cost effective long term regenerative treatment solutions for damaged cartilage through a proprietary allogeneic juvenile chondrocyte platform technology. Our lead product candidates are RevaFlexTM, an engineered cartilage implant for articular knee cartilage repair and restoration, and NuQu®, a minimally invasive cell therapy designed to treat back pain and disability associated with chronic spinal disc degeneration, also known as discogenic back pain. In addition to our pipeline of products in clinical development, ISTO manufactures and markets InQu®, a bone graft extender and substitute for spinal fusion applications that has been used in over 30,000 surgeries at U.S. hospitals to date. For additional information on ISTO, please visit our website at www.istobiologics.com.
NuQu® and InQu® are registered trademarks and RevaFlex™ is a trademark of ISTO Technologies, Inc.
ISTO Technologies, Inc.
Scott Gill, Chief Financial Officer
Lisa M. Wilson, In-Site Communications